# SCYNEXIS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/scynexis

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.scynexis.com
- Total disclosed funding: $48M
- Latest round: Series D (Dec 12, 2011)
- Investors on record: 7

## About

SCYNEXIS, Inc. is a biopharmaceutical company focused on developing innovative antifungal therapies for serious infections. Their pioneering approach addresses the urgent need for effective treatments against antifungal-resistant pathogens.SCYNEXIS, Inc. develops antifungal treatments specifically targeting serious fungal infections. Headquartered in Durham, North Carolina, the company has pivoted its focus over the years, emphasizing the commercialization of its lead drug, Ibrexafungerp. SCYNEXIS, Inc. was founded by a team of experienced professionals in the pharmaceutical industry. The company has engaged in multiple funding rounds, most notably raising USD 45.00 mn in a Private Placement on April 2022, contributing to a total amount raised of USD 45.00 mn. The company's CEO is Marco Taglietti.SCYNEXIS specializes in the development and commercialization of antifungal therapies, focusing on difficult-to-treat fungal infections. Their lead product, Ibrexafungerp, represents a novel class known as 'fungerps' and is designed to combat antifungal-resistant pathogens. The company's products target healthcare providers, particularly hospitals and specialty clinics, where the incidence of these infections is rising. SCYNEXIS markets its products across North America and Europe, addressing the pressing need for effective antifungal treatments.In 2023, SCYNEXIS reported revenue of USD 140.14 mn, alongside an EBITDA of USD -37.12 mn. The company's revenue model is primarily based on direct sales to healthcare institutions and partnerships with pharmaceutical distributors, driven by the sales of Ibrexafungerp through tailored pricing structures for institutional buyers.SCYNEXIS, Inc. plans to utilize its recent funding to further develop and launch new antifungal products aimed at expanding its market reach. The company is targeting additional markets in Europe and Asia for its treatments, with strategic timelines for expansion yet to be disclosed. The funds raised through the latest Private Placement will support ongoing clinical trials and product development efforts, reinforcing the company's commitment to combating antifungal resistance in healthcare settings.

## Funding rounds

- Series D, Dec 12, 2011, $5.5M — Alta Partners, Burrill & Company, Ventech
- Series C, Mar 27, 2008, $14M — SR One, Merial Limited
- Series C, Jul 1, 2002, $29M — Alta Partners, Burrill & Company, Ventech, SR One, KBL Healthcare Ventures, Innovation Capital

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series C, Series D
- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series C, Series D
- Ventech (https://capitalatlas.ai/funds/ventech) — Series C, Series D
- SR One (https://capitalatlas.ai/funds/sr-one) — Series C
- KBL Healthcare Ventures (https://capitalatlas.ai/funds/kbl-healthcare-ventures) — Series C
- Innovation Capital — Series C
- Merial Limited — Series C